Literature DB >> 1831794

Differential sensitivity of CD8+ suppressor and cytotoxic T lymphocyte activity to bacterial monophosphoryl lipid A.

F Esquivel1, C E Taylor, P J Baker.   

Abstract

Treatment with a preparation of monophosphoryl lipid A, known to be capable of abolishing the expression of CD8+ suppressor T cell activity generated during the antibody response to type III pneumococcal polysaccharide (SSS-III), was found to have no adverse effect upon either induction or expression of CD8+ cytotoxic T lymphocyte activity specific for influenza A virus antigens. This suggests that suppressor T cells and cytotoxic T lymphocytes represent functionally distinct subsets of CD8+ T cells which can be differentiated on the basis of their sensitivities to inactivation by monophosphoryl lipid A.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1831794      PMCID： PMC258124          DOI： 10.1128/iai.59.9.2994-2998.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  31 in total

Review 1.  Regulation of magnitude of antibody response to bacterial polysaccharide antigens by thymus-derived lymphocytes.

Authors:  P J Baker
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

2.  Alloantigen-specific suppressor T cells are not inhibited by cyclosporin A, but do require IL 2 for activation.

Authors:  R P Bucy
Journal:  J Immunol       Date:  1986-08-01       Impact factor: 5.422

Review 3.  Cytotoxic T cells in influenza infection.

Authors:  B A Askonas; P M Taylor; F Esquivel
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

4.  Class I MHC molecules rather than other mouse genes dictate influenza epitope recognition by cytotoxic T cells.

Authors:  P M Taylor; J Davey; K Howland; J B Rothbard; B A Askonas
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

5.  Inactivation of suppressor T-cell activity by nontoxic monophosphoryl lipid A.

Authors:  P J Baker; J R Hiernaux; M B Fauntleroy; B Prescott; J L Cantrell; J A Rudbach
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

6.  Characterization of the antibody response to type 3 pneumococcal polysaccharide at the cellular level. II. Studies on the relative rate of antibody synthesis and release by antibody-producing cells.

Authors:  P J Baker; P W Stashak; D F Amsbaugh; B Prescott
Journal:  Immunology       Date:  1971-04       Impact factor: 7.397

7.  Ability of monophosphoryl lipid A to augment the antibody response of young mice.

Authors:  P J Baker; J R Hiernaux; M B Fauntleroy; P W Stashak; B Prescott; J L Cantrell; J A Rudbach
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

8.  Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes.

Authors:  J W Yewdell; J R Bennink; G L Smith; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

9.  Involvement of two distinct regulatory T cell populations in the antigen-specific suppression of cytolytic T cell generation.

Authors:  B H Devens; A W Koontz; J A Kapp; C W Pierce; D R Webb
Journal:  J Immunol       Date:  1991-03-01       Impact factor: 5.422

10.  Functional subclasses of T lymphocytes bearing different Ly antigens. II. Cooperation between subclasses of Ly+ cells in the generation of killer activity.

Authors:  H Cantor; E A Boyse
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307
View more
  3 in total

1.  Molecular structures that influence the immunomodulatory properties of the lipid A and inner core region oligosaccharides of bacterial lipopolysaccharides.

Authors:  P J Baker; T Hraba; C E Taylor; P W Stashak; M B Fauntleroy; U Zähringer; K Takayama; T R Sievert; X Hronowski; R J Cotter
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

2.  Structural features that influence the ability of lipid A and its analogs to abolish expression of suppressor T cell activity.

Authors:  P J Baker; T Hraba; C E Taylor; K R Myers; K Takayama; N Qureshi; P Stuetz; S Kusumoto; A Hasegawa
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

3.  Abrogation of suppression of delayed hypersensitivity induced by Candida albicans-derived mannan by treatment with monophosphoryl lipid A.

Authors:  J E Domer; L G Human; G B Andersen; J A Rudbach; G L Asherson
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.